JP2012506904A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506904A5
JP2012506904A5 JP2011534455A JP2011534455A JP2012506904A5 JP 2012506904 A5 JP2012506904 A5 JP 2012506904A5 JP 2011534455 A JP2011534455 A JP 2011534455A JP 2011534455 A JP2011534455 A JP 2011534455A JP 2012506904 A5 JP2012506904 A5 JP 2012506904A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
active ingredient
pharmaceutically active
mesoporous
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506904A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2009/000053 external-priority patent/WO2010050897A1/en
Publication of JP2012506904A publication Critical patent/JP2012506904A/ja
Publication of JP2012506904A5 publication Critical patent/JP2012506904A5/ja
Pending legal-status Critical Current

Links

JP2011534455A 2008-10-28 2009-02-18 難水溶性成分のためのメソ多孔性材料賦形剤 Pending JP2012506904A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10901608P 2008-10-28 2008-10-28
US61/109,016 2008-10-28
PCT/SG2009/000053 WO2010050897A1 (en) 2008-10-28 2009-02-18 Mesoporous material excipients for poorly aqueous soluble ingredients

Publications (2)

Publication Number Publication Date
JP2012506904A JP2012506904A (ja) 2012-03-22
JP2012506904A5 true JP2012506904A5 (enExample) 2012-05-10

Family

ID=42129067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534455A Pending JP2012506904A (ja) 2008-10-28 2009-02-18 難水溶性成分のためのメソ多孔性材料賦形剤

Country Status (5)

Country Link
US (1) US8778401B2 (enExample)
EP (1) EP2349336B1 (enExample)
JP (1) JP2012506904A (enExample)
KR (1) KR20110110097A (enExample)
WO (1) WO2010050897A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
AU2011303849A1 (en) 2010-09-14 2013-04-04 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
AP3310A (en) 2011-06-20 2015-06-30 Lundbeck & Co As H Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
EP3892285A3 (en) * 2012-11-06 2021-11-17 Sigrid Therapeutics AB A porous silica material for use as a pharmaceutical or dietary active ingredient
WO2014100522A1 (en) 2012-12-21 2014-06-26 National Health Research Institutes Mesoporous silica nanoparticles for oil absorption
US20180185286A1 (en) * 2014-03-31 2018-07-05 Novartis Pharma Ag Porous materials containing compounds including pharmaceutically active species
CN104027814B (zh) * 2014-05-29 2016-02-24 福州大学 一种通过氨基修饰后双重载药的介孔二氧化硅
EP3174527B1 (en) * 2014-08-01 2021-02-17 Johnson & Johnson Consumer Inc. Dosage form of sodium ibuprofen dihydrate on mesoporous silica
US20170135991A1 (en) * 2014-08-01 2017-05-18 Glenmark Pharmaceuticals S.A. NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR
GB201502073D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
US10252251B2 (en) 2015-08-28 2019-04-09 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Production of organic materials using solid catalysts
WO2017208209A1 (en) * 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
CN106755231B (zh) * 2016-11-29 2020-11-24 大连工业大学 一种血管紧张素转化酶抑制肽的提取方法
EP3570848B1 (en) 2017-01-20 2023-06-07 M Et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
CN110678206B (zh) * 2017-05-19 2023-03-21 株式会社德山 医药原料药载体及其制造方法
EP3876991A4 (en) 2018-11-07 2022-09-28 Disruptive Pharma AB NOVEL AMORPHOUS ACTIVE PHARMACEUTICALS WITH ESSENTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE
US11123309B2 (en) 2018-11-15 2021-09-21 Imam Abdulrahman Bin Faisal University Methods for drug delivery, tumor imaging, and oxidative dehydrogenation using hierarchical ZSM-5 complex
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
WO2020154770A1 (en) * 2019-01-31 2020-08-06 Macquarie University Complexes and compositions comprising probucol and uses thereof
JP7260353B2 (ja) * 2019-03-25 2023-04-18 株式会社ファンケル コエンザイムｑ１０の固体分散体
GB201909137D0 (en) * 2019-06-25 2019-08-07 Univ Aston Mesoporous polymeric particulate material
JP2021042173A (ja) * 2019-09-12 2021-03-18 株式会社ファンケル クルクミン固体分散体
US20240016739A1 (en) * 2020-05-06 2024-01-18 Disruptive Pharma Ab Novel amorphous active pharmaceutical ingredients
EP4333817A4 (en) * 2021-05-06 2025-12-31 Univ Hong Kong Chinese REALIZATION OF THE NANO-AMORPHIC STATE OF MATERIALS INSIDE NANOPOROUS MATRICES
US12458602B2 (en) 2021-05-06 2025-11-04 The Chinese University Of Hong Kong Realizing the nano-amorphous state of materials inside nano-porous templates
CN115300448A (zh) * 2021-05-06 2022-11-08 香港中文大学 在纳米多孔模板内实现材料的纳米非晶态

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5922299A (en) 1996-11-26 1999-07-13 Battelle Memorial Institute Mesoporous-silica films, fibers, and powders by evaporation
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7172770B2 (en) 2001-02-19 2007-02-06 Board Of Regents, The University Of Texas System Mesoporous compositions for use in drug delivery
US6630170B2 (en) 2001-04-26 2003-10-07 Board Of Regents The University Of Texas System Mesoporous compositions and method of preparation
HUP0400281A3 (en) * 2001-06-22 2009-11-30 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
WO2005082277A1 (en) 2004-02-18 2005-09-09 Stanford University Drug delivery systems using mesoporous oxide films
WO2005110592A1 (en) * 2004-05-17 2005-11-24 Yki, Ytkemiska Institutet Ab Mesoporous particles loaded with active substance

Similar Documents

Publication Publication Date Title
JP2012506904A5 (enExample)
Patel et al. Xanthan gum derivatives: Review of synthesis, properties and diverse applications
US20240293327A1 (en) Monolithic tablets based on carboxyl polymeric complexes for controlled drug release
Javanbakht et al. Carboxymethyl cellulose-based oral delivery systems
CN112004520B (zh) 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物
JP2008503475A5 (enExample)
CN101466359B (zh) 快速释放的对乙酰氨基酚片
Wang et al. Facile preparation of magnetic 2-hydroxypropyltrimethyl ammonium chloride chitosan/Fe3O4/halloysite nanotubes microspheres for the controlled release of ofloxacin
CA3097737A1 (en) Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CN105283203A (zh) 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
Bera et al. Facile synthesis and characterization of tailor-made pectin-gellan gum-bionanofiller composites as intragastric drug delivery shuttles
Nayak et al. Gellan gum-based nanomaterials in drug delivery applications
WO2011135591A2 (en) Novel tablet composition of polyallylamine polymers
Xie et al. Efficient antibacterial agent delivery by mesoporous silica aerogel
JP2011241218A5 (enExample)
Mali et al. Delivery of drugs using tamarind gum and modified tamarind gum: A review
WO2008086844A2 (en) Co-precipitate, method for preparing the same and uses thereof
JP2011513393A5 (enExample)
RU2004117848A (ru) Система продолжительного высвобождения растворимого лекарственного средства
Davaran et al. RETRACTED ARTICLE: Synthesis of Chemically Cross-Linked Hydroxypropyl Methyl Cellulose Hydrogels and their Application in Controlled Release of 5-Amino Salicylic Acid
JP2010521437A5 (enExample)
JP2002536318A5 (enExample)
Hamidi et al. An overview on current trends and future outlook of hydrogels in drug delivery.
Hasnain et al. Graft copolymers of chitosan in drug delivery applications
Nokhodchi et al. Application of polymer combinations in extended release hydrophilic matrices